All patients (n=84) that undertook rectal resection in our clinic between March 2002 and September 2010, where examined as a part of a retrospective cohort analysis. The median observation period was 50,6 months. All patients were offered an additional therapy with autologous dendritic cells. 39 patients opted for an additive Immunotherapy (+ DC) and 45 patients chose against it (-DC). All patients were treated according to the S3-guidelines.
Immunotherapy with autologous dendritic cells was well tolerated, no serious side effects were observed. In the +DC-group, one local recurrence was observed and 4 patients developed remote metastasis (total: 12,8%), whereas in the -DC group 3 patients experienced local recurrence and 14 patients developed remote metastasis (total: 37,8%, p>0,005). The cancer dependent 5 year survival rate after Kaplan-Meier is 100% for the +DC group and 80,5% in the -DC group (p>0,02). Examining patients in the UICC stage III shows no local recurrence in the +DC group (n=17) and three patients who developed remote metastasis (total: 17,6%) whereas the -DC group (n=18) shows two cases of local recurrence and ten patients developed remote metastasis (total 66,6%, p>0,001). The cancer dependent 5 year survival rate after Kaplan-Meier is 100% in the +DC group and 52,1% in the -DC group (p>0,02).
Within the scope of a retrospective cohort analysis, we could demonstrate that additive immunotherapy with autologous dendritic cells lowers the rates of recurrence and metastasis while dramatically increasing the 5 year survival rates in adjuvant therapy of rectal carcinoma.
Article Reference link: click here
Scientific article publishing date : 26/04/2013
Immucura identifier : BSC21_018EN